publication venue for A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. 18:-. 2016-01-01 Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. 18:-. 2016-01-01 Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. 8:-. 2006-01-01